@article{oai:shiga-med.repo.nii.ac.jp:00000131,
 author = {糸井, 尚子 and 東口, 貴之 and 李, 哲柱 and 阿部, 元 and 来見, 良誠 and 谷, 徹},
 issue = {1},
 journal = {滋賀医科大学雑誌},
 month = {},
 note = {Departmental Bulletin Paper, Paclitaxel is one of the most effective and well tolerated anti-cancer drugs used for advanced metastatic breast����cancer treatment. We treated a 70-year-old woman with metastatic breast cancer who had developed Stevens-Johnsonsyndrome after intravenous administration of the first dose of paclitaxel. Stevens-Johnson syndrome is a rare, severe,immune-mediated cutaneous reaction to medication. Drug lymphocyte stimulation test���� was performed and Paclitaxel waslikely to be a cause of this complication . The patient was treated with steroid pulse therapy with intravenousimmunoglobulin. This case report serves as an alert for the need to observe patients carefully for potentially severe cutaneousreactions to paclitaxel.},
 pages = {31--34},
 title = {再発乳癌患者に対しパクリタキセルを投与した際に発症したStevens-Johnson症候群の一例},
 volume = {24},
 year = {2011}
}